Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
1. 系统已在2026-05-29 14:35:21对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
J Xu, L Zhang, Y Liang, C Ji, A Xu, Z Li, L Li…
JAMA …, 2026
jamanetwork.com
Importance ICP-332 is a tyrosine kinase 2 inhibitor currently under investigation for the treatment of atopic dermatitis (AD). Objective To evaluate the safety and efficacy of ICP-332 for moderate to severe AD. Design, Setting, and Participants This double-blind, placebo-controlled, phase 2 randomized clinical trial was conducted between February 6 and November 7, 2023, across 19 centers in China. Individuals aged 18 to 75 years who had diagnosis of AD for 1 year or longer and a history of contraindication or inadequate …
